#1 Clinical Trials Search in Europe

Humanised Igg1 Monoclonal Antibody Against N-Terminally Truncated Pyroglutamate-3 Ab

This article discusses the ongoing clinical trials of ABBV-916, a humanized IgG1 monoclonal antibody targeting N-terminally truncated pyroglutamate-3 Ab. The drug is being studied as a potential treatment for early Alzheimer’s disease. The trials aim to evaluate the safety, efficacy, and effects of ABBV-916 on reducing amyloid plaques in the brain, which are associated with the progression of Alzheimer’s disease.

Table of Contents

What is ABBV-916?

ABBV-916 is a new medication being studied for the treatment of early Alzheimer’s disease. It is also known as a humanised IgG1 monoclonal antibody against N-terminally truncated pyroglutamate-3 AB.[1] This may sound complicated, but let’s break it down:

  • Humanised: This means the antibody is designed to be similar to human antibodies, reducing the chance of the body rejecting it.
  • IgG1: This is a type of antibody that our immune system naturally produces.
  • Monoclonal antibody: This is a laboratory-made protein that can bind to specific substances in the body.
  • Pyroglutamate-3 AB: This is a specific form of amyloid beta, a protein that builds up in the brains of people with Alzheimer’s disease.

How Does ABBV-916 Work?

ABBV-916 is designed to target and remove a specific form of amyloid beta protein that accumulates in the brains of people with Alzheimer’s disease. By reducing these harmful protein deposits, researchers hope to slow down or potentially stop the progression of early Alzheimer’s disease.[1]

Current Research on ABBV-916

ABBV-916 is currently being studied in a Phase 2 clinical trial. This means that after initial safety testing, researchers are now investigating how well the drug works and continue to monitor its safety in a larger group of people with early Alzheimer’s disease.[1]

The main goals of this study are:

  1. To evaluate the safety and tolerability of ABBV-916
  2. To measure how effectively ABBV-916 reduces amyloid plaques in the brain
  3. To understand how the body processes the drug (pharmacokinetics) and how the drug affects the body (pharmacodynamics)[1]

Who Can Participate in the ABBV-916 Study?

The study is looking for participants who meet specific criteria, including:

  • Adults aged 50 to 90 years old
  • People with early Alzheimer’s disease
  • Individuals with an MMSE score (a test of cognitive function) between 20 and 28
  • Those with evidence of amyloid plaques in their brain, as shown by special brain scans and blood tests[1]

Some people may not be able to participate if they have certain health conditions or are taking specific medications. It’s important to discuss with a healthcare provider to determine eligibility.

Study Design

The study is designed as a randomized, double-blind, placebo-controlled trial. This means:

  • Randomized: Participants are randomly assigned to different groups.
  • Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or a placebo.
  • Placebo-controlled: Some participants receive a placebo (a substance with no active drug) for comparison.[1]

The study consists of several phases:

  1. A screening period of up to 60 days
  2. A 24-week treatment period where participants receive either ABBV-916 or a placebo
  3. A 16-week follow-up period
  4. An optional extension period of about 2 years[1]

ABBV-916 is given as an intravenous (IV) injection once every four weeks during the treatment period.[1]

Potential Benefits of ABBV-916

While it’s important to note that ABBV-916 is still in the research phase and its benefits are not yet proven, the potential benefits being studied include:

  • Reduction of amyloid plaques in the brain
  • Potential slowing of Alzheimer’s disease progression
  • Possible improvement or stabilization of cognitive function[1]

Safety Considerations

As with any medical study, there are potential risks and side effects. The researchers are carefully monitoring participants for any adverse effects. Some safety considerations include:

  • Participants should not have planned surgeries during the study period
  • People with a history of drug or alcohol abuse within the past 2 years are excluded
  • Individuals with certain infections or immune system disorders cannot participate[1]

It’s crucial for potential participants to discuss all possible risks and benefits with their healthcare provider and the study team before deciding to participate in the trial.

Aspect Details
Drug Name ABBV-916
Drug Type Humanised IgG1 monoclonal antibody against N-terminally truncated pyroglutamate-3 Ab
Target Condition Early Alzheimer’s Disease
Study Phase Phase 2
Primary Objective Evaluate safety, tolerability, and amyloid reduction
Administration Intravenous, once every four weeks
Study Design Randomized, Double-Blind, Placebo-Controlled
Study Duration 24-week treatment period, 16-week follow-up, optional 2-year extension
Key Inclusion Criteria Age 50-90, MMSE score 20-28, positive amyloid biomarkers
Primary Endpoint Change in brain amyloid plaque deposition at Week 24

FAQ

  • What is ABBV-916? ABBV-916 is a humanized IgG1 monoclonal antibody designed to target N-terminally truncated pyroglutamate-3 Ab, which is believed to play a role in Alzheimer's disease. It is being studied as a potential treatment for early Alzheimer's disease.
  • How is ABBV-916 administered in the clinical trial? In the clinical trial, ABBV-916 is administered intravenously (through a vein) once every four weeks.
  • Who is eligible to participate in the ABBV-916 clinical trial? Eligible participants are adults aged 50 to 90 years with early Alzheimer's disease. They must have an MMSE score of 20 to 28, a blood-based biomarker result consistent with amyloid PET positivity, and an amyloid PET scan showing amyloid pathology.
  • What is the primary goal of the ABBV-916 clinical trial? The primary goal of the trial is to evaluate the safety, tolerability, and amyloid reduction associated with ABBV-916 after repeated intravenous administrations in subjects with early Alzheimer's disease.
  • How long does the clinical trial last? The trial consists of a screening period of up to 60 days, a 24-week double-blind treatment period, and a 16-week follow-up period. There is also an extension period of approximately 2 years plus an additional 16-week follow-up period.

Ongoing Clinical Trials on Humanised Igg1 Monoclonal Antibody Against N-Terminally Truncated Pyroglutamate-3 Ab

  • Study on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Italy Portugal Spain

Glossary

  • Alzheimer's disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In this case, ABBV-916 is a monoclonal antibody targeting a specific protein associated with Alzheimer's disease.
  • Amyloid PET scan: A type of brain imaging that uses a radioactive tracer to detect amyloid plaques, which are associated with Alzheimer's disease.
  • MMSE (Mini-Mental State Examination): A widely used test of cognitive function used to screen for dementia and assess its progression and severity.
  • Centiloid: A standardized measure used to quantify amyloid burden in the brain, as detected by amyloid PET scans.
  • Double-blind: A study design in which neither the participants nor the researchers know who is receiving the experimental treatment and who is receiving a placebo or standard treatment.
  • Placebo: A substance that has no therapeutic effect, used as a control in testing new drugs.
  • Intravenous (IV) administration: The delivery of a medication directly into a vein using a needle or tube.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-abbv-916-and-mk-6240-for-patients-with-early-alzheimers-disease/